"Prognosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
| Descriptor ID |
D011379
|
| MeSH Number(s) |
E01.789
|
| Concept/Terms |
Prognostic Factors- Prognostic Factors
- Factor, Prognostic
- Factors, Prognostic
- Prognostic Factor
|
Below are MeSH descriptors whose meaning is more general than "Prognosis".
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
- Diagnosis [E01]
- Prognosis [E01.789]
Below are MeSH descriptors whose meaning is more specific than "Prognosis".
This graph shows the total number of publications written about "Prognosis" by people in this website by year, and whether "Prognosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 23 | 23 |
| 1996 | 0 | 22 | 22 |
| 1997 | 0 | 29 | 29 |
| 1998 | 0 | 36 | 36 |
| 1999 | 0 | 29 | 29 |
| 2000 | 0 | 47 | 47 |
| 2001 | 0 | 38 | 38 |
| 2002 | 0 | 39 | 39 |
| 2003 | 0 | 56 | 56 |
| 2004 | 0 | 55 | 55 |
| 2005 | 0 | 62 | 62 |
| 2006 | 0 | 77 | 77 |
| 2007 | 0 | 86 | 86 |
| 2008 | 0 | 85 | 85 |
| 2009 | 0 | 94 | 94 |
| 2010 | 0 | 103 | 103 |
| 2011 | 0 | 127 | 127 |
| 2012 | 0 | 105 | 105 |
| 2013 | 1 | 147 | 148 |
| 2014 | 1 | 171 | 172 |
| 2015 | 0 | 163 | 163 |
| 2016 | 5 | 155 | 160 |
| 2017 | 3 | 186 | 189 |
| 2018 | 1 | 206 | 207 |
| 2019 | 1 | 228 | 229 |
| 2020 | 0 | 212 | 212 |
| 2021 | 1 | 122 | 123 |
| 2022 | 0 | 61 | 61 |
| 2023 | 0 | 77 | 77 |
| 2024 | 0 | 124 | 124 |
| 2025 | 0 | 41 | 41 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prognosis" by people in Profiles.
-
Extremity rhabdomyosarcoma in children, adolescents and young adults: A report from Children's Oncology Group trials. Cancer. 2025 Jun 15; 131(12):e35929.
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomark. 2025 Jun; 42(6):18758592251344936.
-
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study. Neuro Oncol. 2025 May 15; 27(4):1092-1101.
-
Machine learning-based prognostic subgrouping of glioblastoma: A multicenter study. Neuro Oncol. 2025 May 15; 27(4):1102-1115.
-
Pediatric Malignant Tumors in Malawi: A Diagnostic Report From the Kamuzu Central Hospital Pathology Laboratory 2011-2020. Pediatr Blood Cancer. 2025 Jul; 72(7):e31669.
-
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer. Clin Cancer Res. 2025 May 01; 31(9):1615-1624.
-
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial. Breast Cancer Res Treat. 2025 Jul; 212(1):57-69.
-
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025 Jun; 13(6):505-516.
-
Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma. Gut. 2025 Apr 07; 74(5):804-814.
-
Diversity of metabolic features and relevance to clinical subtypes of gliomas. Semin Cancer Biol. 2025 Jul; 112:126-134.